IE921315A1 - Method and assay system for neurothrophin activity - Google Patents

Method and assay system for neurothrophin activity

Info

Publication number
IE921315A1
IE921315A1 IE131592A IE921315A IE921315A1 IE 921315 A1 IE921315 A1 IE 921315A1 IE 131592 A IE131592 A IE 131592A IE 921315 A IE921315 A IE 921315A IE 921315 A1 IE921315 A1 IE 921315A1
Authority
IE
Ireland
Prior art keywords
cell
oligonucleotide
bdnf
tumor
cells
Prior art date
Application number
IE131592A
Other languages
English (en)
Inventor
Stephen P Squinto
Steven H Nye
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IE921315A1 publication Critical patent/IE921315A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
IE131592A 1991-07-03 1992-04-23 Method and assay system for neurothrophin activity IE921315A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72878491A 1991-07-03 1991-07-03
US76267591A 1991-09-20 1991-09-20

Publications (1)

Publication Number Publication Date
IE921315A1 true IE921315A1 (en) 1993-01-13

Family

ID=27111743

Family Applications (1)

Application Number Title Priority Date Filing Date
IE131592A IE921315A1 (en) 1991-07-03 1992-04-23 Method and assay system for neurothrophin activity

Country Status (9)

Country Link
EP (1) EP0593663A4 (ja)
JP (1) JPH06509333A (ja)
AU (1) AU2322392A (ja)
CA (1) CA2112799A1 (ja)
IE (1) IE921315A1 (ja)
IL (1) IL101683A0 (ja)
NZ (1) NZ242467A (ja)
PT (1) PT100424A (ja)
WO (1) WO1993000909A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025683A1 (en) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology A gene which prevents programmed cell death
US6902732B2 (en) 1992-06-12 2005-06-07 Massachusetts Institute Of Technology Identification and characterization of a gene which protects cells from programmed cell death and uses therefor
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE69409641T2 (de) * 1993-05-28 1998-11-26 Cephalon, Inc., West Chester, Pa. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5602309A (en) * 1993-10-04 1997-02-11 University Of Kentucky Research Foundation Transgenic mice which overexpress nerve growth factor
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1997001344A2 (en) * 1995-06-27 1997-01-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1624936B1 (en) * 2003-05-16 2009-10-28 Universite Laval Cns chloride modulation and uses thereof
WO2005110490A1 (en) 2004-05-14 2005-11-24 Universite Laval Phospholipase c gamma modulation and uses thereof for management of pain and nociception
EP3029061B1 (en) 2008-06-18 2017-09-13 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
US20150031750A1 (en) * 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EA201492117A1 (ru) * 2012-05-16 2015-04-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии bdnf

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor

Also Published As

Publication number Publication date
EP0593663A1 (en) 1994-04-27
NZ242467A (en) 1995-06-27
AU2322392A (en) 1993-02-11
EP0593663A4 (en) 1996-10-30
WO1993000909A1 (en) 1993-01-21
PT100424A (pt) 1993-10-29
IL101683A0 (en) 1992-12-30
JPH06509333A (ja) 1994-10-20
CA2112799A1 (en) 1993-01-21

Similar Documents

Publication Publication Date Title
IE921315A1 (en) Method and assay system for neurothrophin activity
US5990088A (en) Method for treating kaposi's sarcoma with antisense oligonucleotides
KR0171210B1 (ko) 암치료용 항감작 올리고뉴클레오티드
Frantz et al. Role of TLR-2 in the activation of nuclear factor κB by oxidative stress in cardiac myocytes
Sherman et al. Basic fibroblast growth factor (bFGF) acts intracellularly to cause the transdifferentiation of avian neural crest-derived Schwann cell precursors into melanocytes
Jaboin et al. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway
Hayden et al. Modulated expression of plasminogen activator system components in cultured cells from dissociated mouse dorsal root ganglia
Fliser et al. Erythropoietin and treatment of non-anemic conditions—cardiovascular protection
Wei et al. CXCL4: NLRP3-mediated pyroptosis product that regulates cardiac fibrosis
US20040162257A1 (en) Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells
US6271205B1 (en) Cancer treatment by expression of differentiation factor receptor
WO2001022970A9 (en) Therapy with 2-5a and interferon
US20050282168A1 (en) Cell surface molecules as markers and therapeutic agents against kidney cancers
CN114729363A (zh) Il-34反义剂及其使用方法
Suzuki et al. Dipyridamole enhances an anti‐proliferative effect of interferon in various types of human tumor cells
Wagner et al. An abnormal response of retinoblastoma cells (Y-79) to neurotrophins
Nakajima et al. Changes in Smad1/5/9 expression and phosphorylation in astrocytes of the rat hippocampus after transient global cerebral ischemia
Shikata et al. Neuronal differentiation in human neuroblastoma cells by nerve growth factor following TrkA up‐regulation by interferon‐γ
CA2227370A1 (en) Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene
US5789187A (en) Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
TW200306200A (en) Use of long pentraxin PTX3 for the preparation of a medicine for the treatment of tumour diseases associated with abnormal activation of growth factor FGF-8
EP0677055A1 (en) Antisense molecules directed against a fibroflast growth factor receptor gene family
HUP0600841A2 (en) Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation
Liu et al. The in vitro effects of CRE‐decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines
KR19990022359A (ko) 시토킨 시그날 트랜스듀서 ｇｐ130 ｍＲＮＡ에 특이적인 올리고뉴클레오티드